Pieris Pharmaceuticals declares Respiratory and Ophthalmology deal with Genentech
Pieris, a clinical-stage biotechnology company, declared that it has entered into a multi-program research collaboration and license collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialise locally delivered respiratory and ophthalmology therapies, which leverage Pieris' proprietary Anticalin® technology.
The research deal will let Pieris to combine its robust discovery engine with Genentech's targets, and its preclinical and clinical development expertise, to develop novel therapies for the treatment of respiratory and ophthalmological dise...
